Literature DB >> 1823871

Pharmacokinetics of an indomethacin pro-drug: apyramide after intravenous administration in dog.

M Cociglio1, J Bres, D Sauvaire, R Alric, M Richard.   

Abstract

The pharmacokinetics of apyramide, an ester of indomethacin and acetaminophen (paracetamol), were determined after intravenous administration to nine beagle dogs. Indomethacin and its pro-drug, apyramide, were extracted from acetonitrile-precipitated plasma by a solvent-demixing procedure and the concentration of these two drugs was measured by a reversed-phase liquid chromatographic assay. The kinetic evolution with time of plasma levels of apyramide and of indomethacin resulting from enzymatic hydrolysis was compared with values obtained for indomethacin injected in equimolar dose. Plasma levels of apyramide quickly decreased and the mean (+/- SD) half life was 0.15 +/- 0.08 h. For metabolic indomethacin, the mean (+/- SD) area under curve was 12.36 +/- 4.80 mg.h/l and the mean (+/- SD) half life of terminal phase was 16.71 +/- 9.46 h. After administration of indomethacin, these values were 17.60 +/- 4.12 mg.h/l and 7.89 +/- 2.20 h, respectively.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1823871     DOI: 10.1007/BF03189972

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  2 in total

1.  IGPHARM: interactive graphic package for pharmacokinetic analysis.

Authors:  C Gomeni; R Gomeni
Journal:  Comput Biomed Res       Date:  1978-08

2.  Bioavailability of indomethacin capsules in humans (III): Correlation with bioavailability in beagle dogs.

Authors:  N Aoyagi; H Ogata; N Kaniwa; A Ejima; H Nakata; J Tsutsumi; T Fujita; I Amada
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-11
  2 in total
  1 in total

1.  Influence of poly(DL-lactide) nanocapsules on the biliary clearance and enterohepatic circulation of indomethacin in the rabbit.

Authors:  F Fawaz; F Bonini; M Guyot; A M Lagueny; H Fessi; J P Devissaguet
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.